Representative(s): Stacy Voight Sara Volz Joyce Girard We will be available to you before, during and after presentation. | Genentech is advocating for solutions and policies that help to advance scientific innovation and ensure patients have access to the medicines they need. Visit our website to learn more: www.gene.com
Tecentriq- As a single agent, is indicated as adjuvant treatment following resection & platinum based chemo for adults with stage 2-3a NSCLC who tumors have >1% PD-L1 of tumor cells as determined by FDA approved test. GNE Lung Cancer Portfolio Interactive PDF A Treatment Option for mHCC Clinical Brochure.pdf Phesgo-Fixed dose, subcutaneous formulation of Perjeta & Trastuzumab for Her 2+ early and metastatic breast cancer patients that is administered in approximately 5 mins. |